Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Royalty Pharma plc
BioCentury | Feb 19, 2025
Deals
Biogen takes territorial rights to Stoke’s Dravet program: Deals Report
Plus: Antithrombotic comes back to Novartis via deal for Anthos, Newleos debuts with portfolio of Roche assets, and more
BioCentury | Dec 2, 2024
Deals
PTC adds $1B up front, ‘more muscle’ for Huntington program via Novartis deal
Biotech retains upside in licensing agreement for oral therapy derived from same splicing platform as SMA drug
BioCentury | May 29, 2024
Deals
Deals Report: Three $1B+ takeouts highlight demand in immunology, renal
Plus: Takeda-Degron to develop molecular glue degraders; Lilly-Aktis collaborate on radiopharmaceuticals; and more
BioCentury | May 24, 2024
Finance
Public Equity Report: Investors see Cytokinetics’ moves as doubt for M&A
Plus: IPO updates from Sunho, Rapport; Bicycle’s massive PIPE; Dyne’s opportunistic follow-on; and more
BioCentury | Feb 6, 2024
Deals
MorphoSys’ long run ends with €2.7B Novartis takeout
Shift to product-focused company positioned German biotech for deal giving former Constellation assets to Swiss pharma
BioCentury | Nov 27, 2023
Product Development
Nov. 27 Quick Takes: BioNTech grows U.K. presence
Plus: FDA approval for SpringWorks, setback for Aldeyra and updates from Sanofi, Regeneron, GSK, Abeona, Roivant, Sosei Heptares, Xenon, Arvinas, Teva
BioCentury | Oct 20, 2023
Deals
Oct. 18 Quick Takes: Merck to pay $4B up front for three Daiichi ADCs
Plus: PTC reaps $1B from sale of Evrysdi royalties and updates from Sirius, BMS and Ultragenyx
BioCentury | Aug 25, 2023
Finance
Aug. 24 Quick Takes: Ferring banks $300M up front in Royalty Pharma deal
Plus: Aprinoia, SPAC terminate merger agreement and Exelixis’ cabozantinib shows PFS benefit in NETs and updates on the IRA, RSV and more
BioCentury | Mar 23, 2023
Deals
March 23 Quick Takes: Moderna, Generation Bio in non-viral genetic medicines pact
Plus: PureTech sells royalty for Karuna’s schizophrenia asset and updates from Dewpoint, Novo Nordisk, Gilead and more
BioCentury | Feb 9, 2023
Product Development
Catalysts beyond cystic fibrosis await Vertex after $8.9B year
Along with its successor to blockbuster Trikafta in CF, the biotech is advancing a diversified pipeline encompassing pain, hematology and kidney disease
Items per page:
1 - 10 of 59